FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) announced today that it was awarded an additional grant of $1.4 million for its CD137 monoclonal antibody program from the Small Business Innovative Research, or SBIR, program of the National Institutes of Health. The first year committed funding is approximately $780,000
